Kyorin's DPP-4 inhibitor shows Phase II promise
This article was originally published in Scrip
Executive Summary
The first Phase II data for Kyorin Pharmaceutical's DPP-4 inhibitor KRP-104 show statistically significant reductions in haemoglobin A1c (HbA